tiprankstipranks
Trending News
More News >

GNI Group’s Gyre Pharmaceuticals Launches Etorel for Pulmonary Fibrosis

Story Highlights
GNI Group’s Gyre Pharmaceuticals Launches Etorel for Pulmonary Fibrosis

Confident Investing Starts Here:

GNI Group ( (JP:2160) ) just unveiled an announcement.

GNI Group’s subsidiary, Gyre Pharmaceuticals, has launched Etorel (Nintedanib Esilate Soft Capsules), marking a strategic advancement in the treatment of pulmonary fibrosis. This launch strengthens Gyre Pharmaceuticals’ position as a global leader in this field, addressing significant unmet clinical needs and expanding its market presence.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

More about GNI Group

GNI Group Ltd. operates in the pharmaceutical industry, focusing on treatments for pulmonary fibrosis and interstitial lung diseases through its subsidiary, Gyre Pharmaceuticals Co., Ltd.

Average Trading Volume: 2,703,411

Technical Sentiment Signal: Buy

Current Market Cap: Yen208.9B

Learn more about 2160 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1